Table 1.
Patient demographics and graft characteristics
| Number (%), or Median (Range) |
||
|---|---|---|
| Age | 51 (2-63) | |
| Gender | M | 15 (71) |
| F | 6 (29) | |
| Disease type | AML | 8 (38) |
| MDS | 6 (29) | |
| RAEB-1 | 3 (14) | |
| CMML | 1 (5) | |
| Unclassified/other | 2 (10) | |
| Treatment-related | 3 (14) | |
| CML | 7 (33) | |
| Accelerated phase | 2 (10) | |
| Chronic phase | 4 (19) | |
| Complex cytogenetics | 1 (5) | |
| Monosomy 7 | 1 (5) | |
| Cytogenetics (AML/MDS) | Poor | 6 (29) |
| Intermediate | 3 (14) | |
| Good | 5 (24) | |
| Remission status at transplant | NR | 14 (67) |
| CR/CCR | 7 (33) | |
| Prior Therapies | 2 (0 – 6, 1 prior transplant) | |
| SCT Donor | Matched Sibling | 13 (62) |
| Matched unrelated | 8 (38) | |
| NK Cell Donor | Parent | 6 (29) |
| Sibling | 9 (43) | |
| Child | 6 (29) | |
| NK product | TNC (×106/kg) | 29.88 (0.98 – 42.5) |
| CD3 (×106/kg) | 0 (0 – 0.17) | |
| CD3 % | 0.02 (0 – 0.62) | |
| CD14 (×106/kg) | 11.41 (0.24 – 20.75)* | |
| CD14 % | 41.77 (9.43 – 53.15)* | |
| CD19 (×106/kg) | 6.2 (0.1 – 21.99)* | |
| CD19 % | 21.84 (9.62 – 73.04)* | |
| CD56+CD3− (×106/kg) | 2.96 (0.02 – 8.32) | |
| CD56+CD3− % | 14.1 (1.5 – 27.5)* | |
| Stem Cell Product | TNC (×108/kg) | 8.07 (1.05 – 20.21) |
| CD3 (×106/kg) | 201 (11.02 – 886.7) | |
| CD34 (×106/kg) | 4.8 (3.63 – 12.47) | |
| NK Product Cell dose level/kg | 1. 106 | 6 (1) |
| 2. 5×106 | 2 (0) | |
| 3. 3×107 | 3 (1) | |
| 4. 3×107+ IL-2 | 10 (3) |
*
excludes CD56-selected products. The three CD56-selected product were > 90% CD56+.